

other action is required under UMRA of 1995.

Congressional Review Act

This rule is not a major rule as defined by the Congressional Review Act (CRA), 5 U.S.C. 804. However, pursuant to the CRA, DEA is submitting a copy of the final rule to both Houses of Congress and to the Comptroller General.

Paperwork Reduction Act of 1995

This action does not impose a new collection of information under the Paperwork Reduction Act of 1995. 44 U.S.C. 3501–3521. This action would not impose recordkeeping or reporting requirements on State or local governments, individuals, businesses, or organizations. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Determination To Make Rule Effective Immediately

As indicated above, this rule finalizes the schedule I control status of *N*-ethylhexedrone, α -PHP, 4-MEAP, MPHP, PV8, and 4-chloro- α -PVP that has already been in effect for over two years by virtue of the temporary scheduling order (84 FR 34291, July 18, 2019) and the subsequent one year extension of that order (86 FR 37672, July 16, 2021). The July 2019 order was effective on the date of publication, and was based on findings by the then-Acting Administrator that the temporary scheduling of these substances was necessary to avoid an imminent hazard to the public safety pursuant to 21 U.S.C. 811(h)(1).

Because this rule finalizes the control status of *N*-ethylhexedrone, α -PHP, 4-MEAP, MPHP, PV8, and 4-chloro- α -PVP that has already been in effect for over two years, it does not alter the legal obligations of any person who handles these substances. Rather, it merely makes permanent the current scheduling status and corresponding legal obligations. Therefore, DEA is

making the rule effective on the date of publication in the **Federal Register**, as any delay in the effective date is unnecessary and would be contrary to the public interest. See 5 U.S.C. 553(d).

List of Subjects in 21 CFR Part 1308

Administrative practice and procedure, Drug traffic control, Reporting and recordkeeping requirements.

For the reasons set out above, DEA amends 21 CFR part 1308 as follows:

PART 1308—SCHEDULES OF CONTROLLED SUBSTANCES

■ 1. The authority citation for part 1308 continues to read as follows:

Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise noted.

■ 2. In § 1308.11, add paragraphs (d)(94) through (99) and remove and reserve paragraphs (h)(42) through (47).

The additions read as follows:

§ 1308.11 Schedule I.

* * * * *
(d) * * *

(94) <i>N</i> -Ethylhexedrone (Other names: α -ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one)	7246
(95) <i>alpha</i> -Pyrrolidinohexanophenone (Other names: α -PHP; α -pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one)	7544
(96) 4-Methyl- <i>alpha</i> -ethylaminopentiphenone (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one)	7245
(97) 4'-Methyl- <i>alpha</i> -pyrrolidinohexiophenone (Other names: MPHP; 4'-methyl- <i>alpha</i> -pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one)	7446
(98) <i>alpha</i> -Pyrrolidinoheptaphenone (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one)	7548
(99) 4'-Chloro- <i>alpha</i> -pyrrolidinovalerophenone (Other names: 4-chloro- α -PVP; 4'-chloro- α -pyrrolidinopentiphenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one)	7443

* * * * *

Anne Milgram,
Administrator.

[FR Doc. 2022–11740 Filed 5–31–22; 8:45 am]

BILLING CODE 4410–09–P

in section II of appendix A, remove the term “TWA 6.61” in the formula and add the term “TWA=16.61” in its place.

[FR Doc. 2022–11613 Filed 5–31–22; 8:45 am]

BILLING CODE 0099–10–P

GL 26A, GL 31, and GL 32, each of which was previously issued on OFAC’s website.

DATES: GL 7A, GL 26A, GL 31, and GL 32 were each issued on May 5, 2022. See **SUPPLEMENTARY INFORMATION** of this publication for additional relevant dates.

FOR FURTHER INFORMATION CONTACT: OFAC: Assistant Director for Licensing, 202–622–2480; Assistant Director for Regulatory Affairs, 202–622–4855; or Assistant Director for Sanctions Compliance & Evaluation, 202–622–2490.

SUPPLEMENTARY INFORMATION:

Electronic Availability

This document and additional information concerning OFAC are available on OFAC’s website: www.treas.gov/ofac.

Background

On May 5, 2022, OFAC, in consultation with the Department of State, issued pursuant to the Russian Harmful Foreign Activities Sanctions

DEPARTMENT OF LABOR

Occupational Safety and Health Administration

29 CFR Part 1910

Occupational Safety and Health Standards

CFR Correction

This rule is being published by the Office of the Federal Register to correct an editorial or technical error that appeared in the most recent annual revision of the Code of Federal Regulations.

■ In Title 29 of the Code of Federal Regulations, Parts 1900 to 1910.999, revised as of July 1, 2021, in § 1910.95,

DEPARTMENT OF THE TREASURY

Office of Foreign Assets Control

31 CFR Part 587

Publication of Russian Harmful Foreign Activities Sanctions Regulations Web General Licenses 7A, 26A, 31, and 32

AGENCY: Office of Foreign Assets Control, Treasury.

ACTION: Publication of Web General Licenses.

SUMMARY: The Department of the Treasury’s Office of Foreign Assets Control (OFAC) is publishing four general licenses (GLs) issued pursuant to the Russian Harmful Foreign Activities Sanctions Regulations: GL 7A,

Regulations, 31 CFR part 587 (the “Regulations”), GL 7A, GL 26A, GL 31, and GL 32, each of which authorize certain transactions prohibited by the Regulations. GL 7A and GL 31 do not contain expiration dates. GL 26A and GL 32 each expire at 12:01 a.m. eastern daylight time, July 12, 2022. The texts of GLs 7A, 26A, 31, and 32 are provided below.

Office of Foreign Assets Control
Russian Harmful Foreign Activities
Sanctions Regulations

31 CFR Part 587

General License No. 7A

Authorizing Overflight Payments, Emergency Landings, and Air Ambulance Services

(a) Except as provided in paragraph (c) of this general license, all transactions ordinarily incident and necessary to the receipt of, and payment of charges for, services rendered in connection with overflights of the Russian Federation or emergency landings in the Russian Federation by aircraft registered in the United States or owned or controlled by, or chartered to, U.S. persons that are prohibited by the Russian Harmful Foreign Activities Sanctions Regulations, 31 CFR part 587 (RuHSR), are authorized.

(b) Except as provided in paragraph (c) of this general license, all transactions ordinarily incident and necessary to provide air ambulance and related medical services, including medical evacuation, to individuals in the Russian Federation that are prohibited by the RuHSR are authorized.

(c) This general license does not authorize:

(1) The opening or maintaining of a correspondent account or payable-through account for or on behalf of any entity subject to Directive 2 under Executive Order 14024, *Prohibitions Related to Correspondent or Payable-Through Accounts and Processing of Transactions Involving Certain Foreign Financial Institutions*; or

(2) Any debit to an account on the books of a U.S. financial institution of the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, or the Ministry of Finance of the Russian Federation.

(d) Effective May 5, 2022, General License No. 7, dated February 24, 2022, is replaced and superseded in its entirety by this General License No. 7A.

Bradley T. Smith,
Deputy Director, Office of Foreign Assets Control.

Dated: May 5, 2022.

Office of Foreign Assets Control
Russian Harmful Foreign Activities
Sanctions Regulations

31 CFR Part 587

General License No. 26A

Authorizing the Wind Down of Transactions Involving Joint Stock Company SB Sberbank Kazakhstan, Sberbank Europe AG, or Sberbank (Switzerland) AG

(a) Except as provided in paragraph (b) of this general license, all transactions ordinarily incident and necessary to the wind down of transactions involving Joint Stock Company SB Sberbank Kazakhstan, Sberbank Europe AG, or Sberbank (Switzerland) AG (collectively, “the blocked Sberbank subsidiaries”), or any entity in which the blocked Sberbank subsidiaries own, directly or indirectly, a 50 percent or greater interest, that are prohibited by Executive Order (E.O.) 14024 are authorized through 12:01 a.m. eastern daylight time, July 12, 2022.

(b) This general license does not authorize:

(1) Any transactions prohibited by Directive 2 under E.O. 14024, *Prohibitions Related to Correspondent or Payable-Through Accounts and Processing of Transactions Involving Certain Foreign Financial Institutions*;

(2) Any transactions prohibited by Directive 4 under E.O. 14024, *Prohibitions Related to Transactions Involving the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, and the Ministry of Finance of the Russian Federation*; or

(3) Any transactions otherwise prohibited by the Russian Harmful Foreign Activities Sanctions Regulations, 31 CFR part 587 (RuHSR), including transactions involving any person blocked pursuant to the RuHSR other than the blocked persons described in paragraph (a) of this general license, unless separately authorized.

(c) Effective May 5, 2022, General License No. 26, dated April 12, 2022, is replaced and superseded in its entirety by this General License No. 26A.

Bradley T. Smith,
Deputy Director, Office of Foreign Assets Control.

Dated: May 5, 2022.

Office of Foreign Assets Control
Russian Harmful Foreign Activities
Sanctions Regulations

31 CFR Part 587

General License No. 31

Authorizing Certain Transactions Related to Patents, Trademarks, and Copyrights

(a) Except as provided in paragraph (b) of this general license, the following transactions in connection with a patent, trademark, copyright, or other form of intellectual property protection in the United States or the Russian Federation that would be prohibited by the Russian Harmful Foreign Activities Sanctions Regulations, 31 CFR part 587 (RuHSR), are authorized:

(1) The filing and prosecution of any application to obtain a patent, trademark, copyright, or other form of intellectual property protection;

(2) The receipt of a patent, trademark, copyright, or other form of intellectual property protection;

(3) The renewal or maintenance of a patent, trademark, copyright, or other form of intellectual property protection; and

(4) The filing and prosecution of any opposition or infringement proceeding with respect to a patent, trademark, copyright, or other form of intellectual property protection, or the entrance of a defense to any such proceeding.

(b) This general license does not authorize:

(1) The opening or maintaining of a correspondent account or payable-through account for or on behalf of foreign financial institutions determined to be subject to the prohibitions of Directive 2 under Executive Order (E.O.) 14024, *Prohibitions Related to Correspondent or Payable-Through Accounts and Processing of Transactions Involving Certain Foreign Financial Institutions*;

(2) Any debit to an account on the books of a U.S. financial institution of the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, or the Ministry of Finance of the Russian Federation; or

(3) Any transactions prohibited by E.O. 14066 or E.O. 14068.

Bradley T. Smith,
Deputy Director, Office of Foreign Assets Control.

Dated: May 5, 2022.

Office of Foreign Assets Control**Russian Harmful Foreign Activities
Sanctions Regulations****31 CFR Part 587****General License No. 32****Authorizing the Wind Down of
Transactions Involving Amsterdam
Trade Bank NV**

(a) Except as provided in paragraph (b) of this general license, all transactions ordinarily incident and necessary to the wind down of transactions involving Amsterdam Trade Bank NV, or any entity in which Amsterdam Trade Bank NV owns, directly or indirectly, a 50 percent or greater interest, that are prohibited by Executive Order (E.O.) 14024 are authorized through 12:01 a.m. eastern daylight time, July 12, 2022.

(b) This general license does not authorize:

(1) Any transactions prohibited by Directive 2 under E.O. 14024, *Prohibitions Related to Correspondent or Payable-Through Accounts and Processing of Transactions Involving Certain Foreign Financial Institutions*;

(2) Any transactions prohibited by Directive 4 under E.O. 14024, *Prohibitions Related to Transactions Involving the Central Bank of the Russian Federation, the National Wealth Fund of the Russian Federation, and the Ministry of Finance of the Russian Federation*; or

(3) Any transactions otherwise prohibited by the Russian Harmful Foreign Activities Sanctions Regulations, 31 CFR part 587 (RuHSR), including transactions involving any person blocked pursuant to the RuHSR other than the blocked persons described in paragraph (a) of this general license, unless separately authorized.

Bradley T. Smith,

Deputy Director, Office of Foreign Assets Control.

Dated: May 5, 2022.

Andrea M. Gacki,

Director, Office of Foreign Assets Control.

[FR Doc. 2022-11760 Filed 5-31-22; 8:45 am]

BILLING CODE P

DEPARTMENT OF DEFENSE**Office of the Secretary****32 CFR Part 199**

[Docket ID: DoD-2020-HA-0040; and DoD-2020-HA-0050]

RIN 0720-AB81; 0720-AB82; and 0720-AB83

**TRICARE Coverage and
Reimbursement of Certain Services
Resulting From Temporary Program
Changes in Response to the COVID-19
Pandemic**

AGENCY: Office of the Assistant Secretary of Defense for Health Affairs, Department of Defense (DoD).

ACTION: Final rule.

SUMMARY: The Assistant Secretary of Defense for Health Affairs (ASD(HA)) issues this final rule related to certain provisions of three TRICARE interim final rules (IFRs) with request for comments issued in 2020 in response to the novel coronavirus disease 2019 (COVID-19) public health emergency (PHE). Temporary coverage of telephonic office visits is made permanent in this final rule, with its adoption expanded beyond the pandemic; the temporary telehealth cost-share waiver is terminated; and the temporary waiver of certain acute care hospital requirements and permanent adoption of Medicare New Technology Add-on Payments for new medical items and services are modified, as further discussed in the **SUPPLEMENTARY INFORMATION** section of this rule

DATES: This rule is effective July 1, 2022, except for instruction 4 (the provision modifying temporary hospitals) which is effective on June 1, 2022. Effective July 1, 2022 the interim final rules amending 32 CFR part 199, which were published at 85 FR 27921, May 12, 2020, and 85 FR 54914, September 3, 2020, are adopted as final with changes, except for the note to paragraph 199.4(g)(15)(i)(A), published at 85 FR 54923, September 3, 2020, which remains interim.

FOR FURTHER INFORMATION CONTACT:

Erica Ferron, Defense Health Agency, Medical Benefits and Reimbursement Section, 303-676-3626 or erica.c.ferron.civ@mail.mil. Sharon Seelmeyer, Defense Health Agency, Medical Benefits and Reimbursement Section, 303-676-3690 or Sharon.l.seelmeyer.civ@mail.mil, Diagnosis Related Groups, Hospital Value Based Purchasing, Long Term Care Hospitals, and New Technology Add-On Payments.

SUPPLEMENTARY INFORMATION:**I. Executive Summary***A. Purpose of the Rule*

In response to the novel coronavirus (SARS-CoV-2), which causes COVID-19, and the President's declared national emergency for the resulting pandemic (Proclamation 9994, 85 FR 15337 (March 18, 2020)), the ASD(HA) issued three IFRs in 2020 to make temporary modifications to TRICARE regulations in order to better respond to the pandemic. The first IFR, published in the FR on May 12, 2020 (85 FR 27921), temporarily: (1) Modified the TRICARE regulations to allow for coverage of medically necessary telephonic (audio-only) office visits; (2) permitted interstate and international practice by TRICARE providers when such practice was permitted by state, federal, or host-nation law; and (3) waived cost-shares and copayments for covered telehealth services for the duration of the COVID-19 pandemic.

The second IFR, published in the FR on September 3, 2020 (85 FR 54914) temporarily: (1) Waived the three-day prior hospital qualifying stay requirement for skilled nursing facilities (SNFs); (2) added coverage for the treatment use of investigational drugs under expanded access authorized by the U.S. Food and Drug Administration (FDA) when indicated for the treatment of COVID-19; (3) waived certain provisions for acute care hospitals in order to permit TRICARE authorization of temporary hospital facilities and freestanding ambulatory surgical centers (ASCs) providing inpatient and outpatient services to be reimbursed; (4) revised the diagnosis related group reimbursement (DRG) at a 20 percent higher rate for COVID-19 patients; and (5) waived certain requirements for long term care hospitals (LTCHs). The second IFR also included two permanent provisions adopting Medicare's NTAPs adjustment to DRGs for new medical services and technologies and adopting Medicare's Hospital Value Based Purchasing (HVBP) Program.

The third IFR, published in the FR on October 30, 2020 (85 FR 68753) added coverage of National Institute of Allergy and Infectious Disease (NIAID)-sponsored clinical trials when for the prevention or treatment of COVID-19 or its associated sequelae.

After publication of each IFR, DoD evaluated the appropriateness of each temporary measure for continued use throughout the national emergency for COVID-19, as well as to determine if it would be appropriate to make any of the provisions permanent within the